What if someone actually develops a disease (which is told to be highly contagious) as a direct result of vaccination??
Just saw on the CNN (running line on 31st channel) : it's decided not to destroy US-based samples of smallpox virus and to let numerous labs to keep it alive "until new vaccines and treatments are developed", which makes them more available...even for bad-meaning guys.
Another one of ABC News:
(OMG, it hit me just as i was cutting and pasting this article, that those companies may in fact be ones who STARTED anthrax attacks - it wouldn't be the first known case of murder for profit). Am I getting crazy, or the world around us is??
1. These companies are said to be based in Boca Raton, FL and New Jersey - LOCATIONS WHERE ANTHRAX INFECTIONS INITIALLY APPEARED AND POSSIBLY ORIGINATED;
2. They directly exploited public fear of anthrax spread and tried to PROFIT from it IMMEDIATELY.
IS THERE A CHANCE THAT THOSE COMPANIES ACTUALLY STARTED ANTHRAX ATTACK TO EXPLOIT PUBLIC FEARS AND GOVERNMENT PREPARATIONS FOR PROFIT????
3. Just a thought: DO THOSE COMPANIES HAVE ACCESS TO ANTHRAX BACTERIA CULTURES, as they have to be experimenting with them developing their "anti-bioterrorism technologies"?
http://abcnews.go.com/wire/US/reuters20011115_555.html
SEC Says Firms Exploited Bioterror Fears
By Peter Ramjug
WASHINGTON (Reuters) - Federal securities regulators settled cases on Thursday against three companies accused of trying to exploit the public's bioterrorism fears by claiming to have "anti-terrorism" technologies.
The Securities and Exchange Commission said Disease Sciences Inc. of Boca Raton, Florida, and Classica Group Inc. of Lakewood, New Jersey, issued news releases saying they had technologies capable of killing anthrax in mail.
"In fact, neither company had a technology that had been tested or otherwise shown to be effective ... for that purpose," the SEC said.
A press release by a third company, R-Tec Technologies Inc. of Flanders, New Jersey, falsely claimed that it had developed and patented a system "to protect civilians in every day life from biological and chemical terrorism attacks," the SEC said.
The commission said it found that no such system had been developed, patented, or tested.
R-Tec's lawyer, Jerry Selzers, said, "There is a provisional patent application on the system. The system has not been tested, but nor did the company ever claim it had been tested."
The three companies settled the cases by agreeing to a cease-and-desist order, without admitting or denying the charges. They did not have to pay fines.
Classica's lawyer, Robert Kipnees, said the SEC action involved press releases on Oct. 11 and 12, and that since then, the company had issued releases "which we believe fairly and accurately" described the status of its technologies.
"We've had some positive findings so far," he added.
Officials from Disease Sciences did not immediately return a call seeking comment.
The SEC said the news releases were issued between early October and November when the nation was gripped by news of anthrax-related deaths and mail contamination.
The investor protection agency, criticized in the past for moving too slowly, said it acted quickly in these cases under a new policy of real-time enforcement.
"The conduct that led to these enforcement actions is reprehensible," Stephen Cutler, head of the SEC's fraud-fighting enforcement division, said in a statement. "Any effort to profit by spreading false information that plays on people's fear is unconscionable. Today's enforcement actions make clear that the commission will act in real time to sanction such conduct," he added.
The stock of Disease Sciences fell 6 cents, or 43 percent, to close at 8 cents while R-Tec dropped 11 cents, or 14.7 percent, to 64 cents. Both trade on the Bulletin Board.
Classica shares slipped 65 cents, or 24 percent, to close at $2.10 on Nasdaq. The stock has swung from $7 to $1.75 in the past 52 weeks.
